PriceTargets.com logo

Dominari - DOMH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.19 As of 12/4/2025 05:00 PM ET
▼ -0.09 (-2.10%)

This chart shows the closing price for DOMH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dominari Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOMH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOMH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Dominari in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.19.

This chart shows the closing price for DOMH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Dominari. This rating changed within the last month from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/26/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/20/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/14/2025Weiss RatingsUpgradeSell (D-) ➝ Hold (C-)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Dominari logo
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.19
Low: $4.15
High: $4.30

50 Day Range

MA: $5.46
Low: $4.18
High: $7.42

52 Week Range

Now: $4.19
Low: $0.83
High: $13.58

Volume

254,071 shs

Average Volume

214,443 shs

Market Capitalization

$67.08 million

P/E Ratio

0.75

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Dominari?

The following Wall Street research analysts have issued research reports on Dominari in the last year: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for DOMH.

What is the current price target for Dominari?

0 Wall Street analysts have set twelve-month price targets for Dominari in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Dominari in the next year.
View the latest price targets for DOMH.

What is the current consensus analyst rating for Dominari?

Dominari currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DOMH, but not buy more shares or sell existing shares.
View the latest ratings for DOMH.

What other companies compete with Dominari?

Other companies that are similar to Dominari include Vanda Pharmaceuticals, Achieve Life Sciences, Crescent Biopharma, SAB Biotherapeutics and Codexis. Learn More about companies similar to Dominari.

How do I contact Dominari's investor relations team?

Dominari's physical mailing address is One Rockefeller Plaza, 11Th Floor, New York, New York 10020. The company's listed phone number is (112) 745-1374 and its investor relations email address is [email protected]. The official website for Dominari is aikidopharma.com. Learn More about contacing Dominari investor relations.